Abstract
Interest in prognostic factors for breast cancer has been stimulated by the success of systemic adjuvant therapy for early-stage operable disease. Patients destined for recurrence can be selected for systemic adjuvant therapy, while patients not likely to recur can be spared the morbidity of unnecessary treatment. The number of tumor-related features available for prognosis has grown impressively in recent years. The purpose of this article is to review tumor-related biologic factors and relate them to prognosis and treatment objectives.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
